Soundtrack-F1: A phase 3 trial of Surovatamig (AZD0486) with rituximab in people with untreated follicular lymphoma

This trial aims to see how safe and effective the treatment Surovatamig (AZD0486) is when given with rituximab in adults with untreated follicular lymphoma (FL).

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06549595

Trial aim and background  

The aim of this trial is to see how safe and effective the treatment Surovatamig (AZD0486) is, as well as how it compares to current treatment options in people with untreated FL. 

The study consists of two parts:

  1. The first part aims to establish a suitable dose by comparing dose levels of Surovatamig
  2. The second part will use this dose to compare its effectiveness in combination with rituximab against 3 standard chemoimmunotherapy regimens

Who can enter 

Adults with grade 1 – 3A FL who have received no prior treatment may be eligible for this trial.

Locations 

Recruitment is taking place in:

  • London
  • Newcastle upon Tyne
  • Norwich
  • Nottingham
  • Plymouth

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT06549595

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.